Histone deacetylase inhibitor valproic acid affects plasmacytoid dendritic cells phenotype and function

Immunobiology

Volumn 219, Issue 8, 2014, Pages 637-643

  Arbez, Jessy ^a,b,c   Lamarthée, Baptiste ^a,b,c   Gaugler, Béatrice ^a,b,c   Saas, Philippe ^a,b,c,d  

^a France   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d Plateforme de Biomonitoring   (France)

Author keywords

Cytokines; HDAC inhibitor; Plasmacytoid dendritic cells

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; AUTACOID; CPG-OLIGONUCLEOTIDE; CYTOKINE; HISTONE DEACETYLASE INHIBITOR; LEUKOCYTE ANTIGEN; OLIGODEOXYRIBONUCLEOTIDE;

ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; COCULTURE; CPG ISLAND; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTERFERON PRODUCTION; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SUPERNATANT; CELL CULTURE; CELL DIFFERENTIATION; DENDRITIC CELL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PHYSIOLOGIC MONITORING;

ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MONITORING, PHYSIOLOGIC; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; VALPROIC ACID;

EID: 84902078711     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.03.013     Document Type: Article

References (31)

1. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25:383.
2. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., Colonna M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 1999, 5:919.
3. Cella M., Facchetti F., Lanzavecchia A., Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat. Immunol. 2000, 1:305.
4. Chauhan D., Singh A.V., Brahmandam M., Carrasco R., Bandi M., Hideshima T., Bianchi G., Podar K., Tai Y.T., Mitsiades C., Raje N., Jaye D.L., Kumar S.K., Richardson P., Munshi N., Anderson K.C. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009, 16:309.
5. Choi S., Reddy P. HDAC inhibition and graft versus host disease. Mol. Med. 2011, 17:404.
6. Colonna M., Trinchieri G., Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219.
7. Dimopoulos M., Siegel D.S., Lonial S., Qi J., Hajek R., Facon T., Rosinol L., Williams C., Blacklock H., Goldschmidt H., Hungria V., Spencer A., Palumbo A., Graef T., Eid J.E., Houp J., Sun L., Vuocolo S., Anderson K.C. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013, 14:1129.
8. + T cells. Cancer Res. 2012, 72:6130.
9. Farkas L., Beiske K., Lund-Johansen F., Brandtzaeg P., Jahnsen F.L. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 2001, 159:237.
10. Frikeche J., Peric Z., Brissot E., Gregoire M., Gaugler B., Mohty M. Impact of HDAC inhibitors on dendritic cell functions. Exp. Hematol. 2012, 40:783.
11. Frikeche J., Simon T., Brissot E., Gregoire M., Gaugler B., Mohty M. Impact of valproic acid on dendritic cells function. Immunobiology 2012, 217:704.
12. Gagliani N., Magnani C.F., Huber S., Gianolini M.E., Pala M., Licona-Limon P., Guo B., Herbert D.R., Bulfone A., Trentini F., Di Serio C., Bacchetta R., Andreani M., Brockmann L., Gregori S., Flavell R.A., Roncarolo M.G. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat. Med. 2013, 19:739.
13. Gilliet M., Cao W., Liu Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 2008, 8:594.
14. Glauben R., Siegmund B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol. Med. 2011, 17:426.
15. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772.
16. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., Cao W., Su B., Nestle F.O., Zal T., Mellman I., Schroder J.M., Liu Y.J., Gilliet M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564.
17. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459.
18. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., Dona G., Fossati G., Sozzani S., Azam T., Bufler P., Fantuzzi G., Goncharov I., Kim S.H., Pomerantz B.J., Reznikov L.L., Siegmund B., Dinarello C.A., Mascagni P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2995.
19. Litvak V., Ratushny A.V., Lampano A.E., Schmitz F., Huang A.C., Raman A., Rust A.G., Bergthaler A., Aitchison J.D., Aderem A. A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. Nature 2012, 490:421.
20. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38.
21. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., Burg G., Liu Y.J., Gilliet M. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 2005, 202:135.
22. Pratt G. Histone deacetylase inhibitors in multiple myeloma. Lancet Oncol. 2013, 14:1038.
23. Reddy P., Sun Y., Toubai T., Duran-Struuck R., Clouthier S.G., Weisiger E., Maeda Y., Tawara I., Krijanovski O., Gatza E., Liu C., Malter C., Mascagni P., Dinarello C.A., Ferrara J.L. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 2008, 118:2562.
24. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., Liu Y.J. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999, 283:1183.
25. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17:330.
26. Roger T., Lugrin J., Le Roy D., Goy G., Mombelli M., Koessler T., Ding X.C., Chanson A.L., Reymond M.K., Miconnet I., Schrenzel J., Francois P., Calandra T. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011, 117:1205.
27. Ronnblom, Eloranta M.L. The interferon signature in autoimmune diseases. Curr. Opin. Rheumatol. 2013, 25:248.
28. Salvi V., Bosisio D., Mitola S., Andreoli L., Tincani A., Sozzani S. Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. Immunobiology 2010, 215:756.
29. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., Antonenko S., Liu Y.J. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835.
30. Sisirak V., Faget J., Gobert M., Goutagny N., Vey N., Treilleux I., Renaudineau S., Poyet G., Labidi-Galy S.I., Goddard-Leon S., Durand I., Le Mercier I., Bajard A., Bachelot T., Puisieux A., Puisieux I., Blay J.Y., Menetrier-Caux C., Caux C., Bendriss-Vermare N. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 2012, 72:5188.
31. Song W., Tai Y.T., Tian Z., Hideshima T., Chauhan D., Nanjappa P., Exley M.A., Anderson K.C., Munshi N.C. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011, 25:161.